Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yu Chiu

Physical Medicine & Rehabilitation Newark, DE Doctor of Osteopathy

NPI 1306227640 CMS profile 6349720

4106 Ogletown Stanton Rd, Newark, DE 19713

Open in the dashboard

General payments

$23,115

209 records reported · program years 2019–2025

Research payments

$1,025

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yu Chiu of Newark, DE is reported in the CMS Open Payments database as having received $23,115 across 209 general payments and $1,025 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,251 19
2024 General $286 4
2023 General $384 12
2022 General $3,805 46
2021 General $9,295 50
2021 Research $1,025 1
2020 General $3,489 41
2019 General $4,605 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yu Chiu
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Yu Chiu were reported at $1,251. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Yu Chiu Physical Medicine & Rehabilitation median Middle half National median
2019 $4,605 $133 $45–$390 $163
2020 $3,489 $88 $29–$272 $114
2021 $9,295 $116 $33–$360 $132
2022 $3,805 $123 $40–$378 $149
2023 $384 $131 $43–$396 $160
2024 $286 $141 $45–$409 $164
2025 $1,251 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GRT US Holding, Inc. $6,323 21 payments
  2. Medtronic, Inc. $5,548 72 payments
  3. Abbott Laboratories $3,202 19 payments
  4. Boston Scientific Corporation $2,236 22 payments
  5. Medtronic USA, Inc. $1,635 25 payments
  6. Nevro Corp. $1,623 22 payments
  7. Arthrex, Inc. $1,364 3 payments
  8. Liberty Surgical, Inc $313 3 payments
  9. Globus Medical, Inc. $169 1 payment
  10. Avanos Medical $123 1 payment
  11. Other $579 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $8,699 45 payments
  2. Food and Beverage $7,816 162 payments
  3. Consulting Fee $5,400 1 payment
  4. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. Qutenza $6,323 21 payments
  2. VANTA ADAPTIVESTIM $2,777 20 payments
  3. Proclaim Family of SCS IPGs $2,345 9 payments
  4. SPECTRA WAVEWRITER $1,963 13 payments
  5. Senza Spinal Cord Stimulation System $1,460 19 payments
  6. INTELLIS $1,129 15 payments
  7. RESTORE $612 5 payments
  8. INTELLIS ADAPTIVESTIM $525 10 payments
  9. INCEPTIV $425 7 payments
  10. VECTRIS $414 8 payments
  11. Other $3,838 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $1,025 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

101

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$2,381

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 52 $1,071
Pregabalin Generic 19 $747
Tizanidine Hcl Generic 30 $563

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$18,439

Medicare's payments for the services billed

Medicare patients

116

Average age 73

Services billed

366

71 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 36%
Diabetes 34%
Chronic kidney disease 34%
Ischemic heart disease 28%
Atrial fibrillation 27%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record